These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 2506596)

  • 1. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.
    Prosser ES; Pruthi R; Csernansky JG
    Psychopharmacology (Berl); 1989; 99(1):109-16. PubMed ID: 2506596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
    Meller E
    Psychopharmacology (Berl); 1982; 76(3):222-7. PubMed ID: 6808540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
    Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors.
    Prosser ES; Csernansky JG; Hollister LE
    Life Sci; 1988; 43(8):715-20. PubMed ID: 2901023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.
    Jenner P; Rupniak NM; Marsden CD
    Psychopharmacology Suppl; 1985; 2():174-81. PubMed ID: 3159009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
    Rupniak NM; Mann S; Hall MD; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1984; 84(4):503-11. PubMed ID: 6441951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
    Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
    Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
    Koller W; Curtin J; Fields J
    Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
    Seeger TF; Thal L; Gardner EL
    Psychopharmacology (Berl); 1982; 76(2):182-7. PubMed ID: 6805029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics.
    Memo M; Battaini F; Spano PF; Trabucchi M
    Acta Psychiatr Scand; 1981 Apr; 63(4):314-24. PubMed ID: 7315480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
    Chivers JK; Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1988 Sep; 40(9):613-9. PubMed ID: 2907027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic haloperidol-amphetamine interactions and mesolimbic dopamine.
    Lynch MR; Kuhn HG; Carey RJ
    Neuropsychobiology; 1988; 19(2):97-103. PubMed ID: 3226530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
    Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
    Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated treatment with (-)-sulpiride plus a low dose of SCH 23390 displays wider neuroleptic activity without inducing dopaminergic supersensitivity.
    Dall'Olio R; Gandolfi O; Roncada P; Vaccheri A; Montanaro N
    Psychopharmacology (Berl); 1990; 100(4):560-2. PubMed ID: 1969667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
    Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs.
    Rupniak NM; Hall MD; Kelly E; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    J Neural Transm; 1985; 62(3-4):249-66. PubMed ID: 2863324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity.
    Jenner P; Hall MD; Murugaiah K; Rupniak N; Theodorou A; Marsden CD
    Biochem Pharmacol; 1982 Feb; 31(3):325-8. PubMed ID: 7200363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.